Novanta Inc. (NASDAQ:NOVT – Get Free Report) CEO Matthijs Glastra sold 6,500 shares of the stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $161.13, for a total value of $1,047,345.00. Following the sale, the chief executive officer owned 29,761 shares of the company’s stock, valued at approximately $4,795,389.93. This represents a 17.93% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Matthijs Glastra also recently made the following trade(s):
- On Tuesday, May 12th, Matthijs Glastra sold 7,500 shares of Novanta stock. The stock was sold at an average price of $150.43, for a total value of $1,128,225.00.
- On Friday, April 17th, Matthijs Glastra sold 6,500 shares of Novanta stock. The stock was sold at an average price of $130.05, for a total value of $845,325.00.
Novanta Stock Down 10.3%
Novanta stock traded down $17.04 during midday trading on Tuesday, reaching $147.85. The company’s stock had a trading volume of 931,197 shares, compared to its average volume of 472,019. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.56 and a quick ratio of 2.69. The stock has a market capitalization of $5.58 billion, a P/E ratio of 107.14 and a beta of 1.67. The stock’s 50-day simple moving average is $153.42 and its 200-day simple moving average is $137.55. Novanta Inc. has a 52-week low of $98.27 and a 52-week high of $171.85.
Analysts Set New Price Targets
NOVT has been the subject of several research reports. Robert W. Baird set a $180.00 price objective on shares of Novanta in a research note on Tuesday, June 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Novanta in a research report on Friday, April 17th. Finally, Wall Street Zen upgraded Novanta from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. One research analyst has rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Novanta has a consensus rating of “Hold” and an average price target of $180.00.
Check Out Our Latest Stock Report on Novanta
Institutional Trading of Novanta
Several institutional investors and hedge funds have recently bought and sold shares of the business. Harbor Investment Advisory LLC acquired a new stake in shares of Novanta in the second quarter worth $54,000. Central Pacific Bank Trust Division lifted its position in Novanta by 26.9% during the second quarter. Central Pacific Bank Trust Division now owns 4,207 shares of the technology company’s stock valued at $683,000 after purchasing an additional 892 shares during the period. Summitry LLC lifted its position in Novanta by 14.6% during the first quarter. Summitry LLC now owns 4,304 shares of the technology company’s stock valued at $508,000 after purchasing an additional 549 shares during the period. Argent Capital Management LLC boosted its holdings in Novanta by 55.4% in the first quarter. Argent Capital Management LLC now owns 7,670 shares of the technology company’s stock valued at $906,000 after purchasing an additional 2,735 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Novanta by 18.3% during the 1st quarter. Bank of America Corp DE now owns 456,241 shares of the technology company’s stock worth $53,887,000 after purchasing an additional 70,728 shares during the period. 98.35% of the stock is currently owned by institutional investors and hedge funds.
Novanta Company Profile
Novanta, Inc (NASDAQ: NOVT) is a global technology company that designs and manufactures precision components, subsystems and software used in advanced photonics and motion control applications. The company serves customers in the medical device and advanced industrial markets, supplying critical technologies for diagnostics and therapeutic systems, semiconductor and electronics manufacturing, and scientific instrumentation. Novanta’s product portfolio includes laser control modules, optics, beam delivery systems, high-precision motors, actuators, stages, and fluidics solutions designed to meet stringent accuracy and reliability requirements.
Novanta’s Photonics segment delivers laser and energy delivery components that enable minimally invasive surgical procedures and diagnostic imaging.
Featured Articles
- Five stocks we like better than Novanta
- Apple and Broadcom Forge a Decade-Long Silicon Fortress
- SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade
- The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity
- Palantir’s CEO Just Called Out OpenAI and Anthropic
Receive News & Ratings for Novanta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novanta and related companies with MarketBeat.com's FREE daily email newsletter.
